Time course toxicogenomic profiles in CD-1 mice after nontoxic and nonlethal hepatotoxic paracetamol administration

D P Williams1, C Garcia-Allan, G Hanton

  • 1Department of Pharmacology and Therapeutics, University of Liverpool, Sherrington Building, Ashton Street, P.O. Box 147, Liverpool, Merseyside L69 3GE, United Kingdom. dom@liv.ac.uk

Insights

Drug-induced liver injury is a significant clinical issue. This study used GeneChip technology to analyze gene expression changes in mice after paracetamol (APAP) exposure, revealing key genetic events underlying hepatotoxicity.

Area of Science:

  • Toxicology
  • Genomics
  • Hepatology

Background:

  • Adverse drug reactions, particularly drug-induced hepatotoxicity, pose a major clinical challenge.
  • Understanding the early genetic events in drug-induced biological changes is crucial for mitigating these reactions.

Purpose of the Study:

  • To investigate global genetic events in mouse liver following non-toxic and toxic doses of paracetamol (APAP).
  • To identify early "decision-making" genetic processes involved in drug-induced hepatotoxicity.

Main Methods:

  • Utilized GeneChip technology to analyze hepatic RNA from mice treated with vehicle, non-toxic APAP (1 mmol/kg), or toxic APAP (3.5 mmol/kg).
  • Performed statistical analysis to identify significantly regulated genes (P < 4.1 x 10(-6)) and categorized them by function (antioxidant, glutathione, metabolism, transcription, immune, apoptosis).
  • Assessed hepatic stress using serum alanine aminotransferase levels and created time-course expression profiles for selected genes.

Main Results:

  • No hepatic stress was observed at the non-toxic APAP dose (1 mmol/kg).
  • Hepatic toxicity manifested 4 and 24 hours after the toxic APAP dose (3.5 mmol/kg).
  • Significant gene expression changes occurred around 4 hours post-toxic APAP dose, with down-regulation observed over 24 hours, coinciding with overt toxicity.

Conclusions:

  • Gene expression profiling provides insights into the in vivo time course of liver responses to chemical stress.
  • This study offers a foundation for investigating new chemical entities and understanding drug-induced hepatotoxicity mechanisms.

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess the...
Toxicokinetics: Overview01:21

Toxicokinetics: Overview

Studies that assess how a drug is absorbed, distributed, metabolized, and excreted (ADME) at toxic doses are termed toxicokinetics. Understanding toxicokinetics helps predict adverse drug reactions (ADRs) and manage toxicity in humans.Toxicokinetics differs from pharmacokinetics mainly in the dose levels studied, with toxicokinetics focusing on higher toxic doses. The kinetics at these levels can be non-linear due to altered physiological processes. Toxicodynamics examines the relationship...
Toxicity Testing in Animals01:23

Toxicity Testing in Animals

Toxicity tests in animals are grounded on two main assumptions: first, the effects observed in laboratory animals can be extrapolated to humans, especially when adjusted for body surface area; second, high-dose exposure in animals is essential to identify potential human hazards from lower doses. This is based on the quantal dose-response concept, which faces the challenge of extrapolating results from relatively few test animals to much larger human populations. For example, a 0.01% incidence...